BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27864876)

  • 21. RET/PTC rearrangement occurring in primary peritoneal carcinoma.
    Flavin R; Jackl G; Finn S; Smyth P; Ring M; O'Regan E; Cahill S; Unger K; Denning K; Jinghuan Li ; Aherne S; Tallini G; Gaffney E; O'Leary JJ; Zitzelsberger H; Sheils O
    Int J Surg Pathol; 2009 Jun; 17(3):187-97. PubMed ID: 19147513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of ROS1 rearrangement in gastric adenocarcinoma.
    Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
    Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF fusions identified in melanomas have variable treatment responses and phenotypes.
    Turner JA; Bemis JGT; Bagby SM; Capasso A; Yacob BW; Chimed TS; Van Gulick R; Lee H; Tobin R; Tentler JJ; Pitts T; McCarter M; Robinson WA; Couts KL
    Oncogene; 2019 Feb; 38(8):1296-1308. PubMed ID: 30254212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.
    Wijesinghe P; Bepler G; Bollig-Fischer A
    J Thorac Oncol; 2015 Feb; 10(2):381-6. PubMed ID: 25384172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
    Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.
    Niu HT; Zhou QM; Wang F; Shao Q; Guan YX; Wen XZ; Chen LZ; Feng QS; Li W; Zeng YX; Zhang XS
    Pigment Cell Melanoma Res; 2013 Sep; 26(5):646-53. PubMed ID: 23751074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ROS1 fusions in cancer: a review.
    Uguen A; De Braekeleer M
    Future Oncol; 2016 Aug; 12(16):1911-28. PubMed ID: 27256160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.
    Saito M; Suzuki H; Kono K; Takenoshita S; Kohno T
    Surg Today; 2018 Jan; 48(1):1-8. PubMed ID: 28280984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?
    Kadokura A; Frydenlund N; Leone DA; Yang S; Hoang MP; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M
    Hum Pathol; 2016 Jul; 53():82-90. PubMed ID: 26980030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma].
    Zhu XL; Zhou XY; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):270-4. PubMed ID: 16181547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment implications of the emerging molecular classification system for melanoma.
    Romano E; Schwartz GK; Chapman PB; Wolchock JD; Carvajal RD
    Lancet Oncol; 2011 Sep; 12(9):913-22. PubMed ID: 21349766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.
    Matsuura S; Shinmura K; Kamo T; Igarashi H; Maruyama K; Tajima M; Ogawa H; Tanahashi M; Niwa H; Funai K; Kohno T; Suda T; Sugimura H
    Oncol Rep; 2013 Oct; 30(4):1675-80. PubMed ID: 23877438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.
    Davies KD; Le AT; Sheren J; Nijmeh H; Gowan K; Jones KL; Varella-Garcia M; Aisner DL; Doebele RC
    J Thorac Oncol; 2018 Oct; 13(10):1474-1482. PubMed ID: 29935306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
    Drilon A; Hu ZI; Lai GGY; Tan DSW
    Nat Rev Clin Oncol; 2018 Mar; 15(3):151-167. PubMed ID: 29134959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
    Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
    Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of fusions with potential clinical significance in melanoma.
    Moran JMT; Le LP; Nardi V; Golas J; Farahani AA; Signorelli S; Onozato ML; Foreman RK; Duncan LM; Lawrence DP; Lennerz JK; Dias-Santagata D; Hoang MP
    Mod Pathol; 2022 Dec; 35(12):1837-1847. PubMed ID: 35871080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack USP6, ROS1 and ETV6 gene rearrangements.
    Jebastin JAS; Smith SC; Perry KD; Gupta NS; Alanee S; Carskadon S; Chitale DA; Palanisamy N; Williamson SR
    Histopathology; 2018 Aug; 73(2):321-326. PubMed ID: 29617048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
    Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
    BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.